Analysts Set Expectations for ChromaDex FY2024 Earnings

ChromaDex Co. (NASDAQ:CDXC) – Equities researchers at HC Wainwright upped their FY2024 earnings estimates for ChromaDex in a report issued on Monday, November 4th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.06 for the year, up from their prior forecast of $0.03. HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for ChromaDex’s current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for ChromaDex’s Q4 2024 earnings at $0.04 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.06 EPS.

ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 5.06%. The business had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. During the same quarter last year, the business earned ($0.01) earnings per share.

ChromaDex Price Performance

NASDAQ CDXC opened at $5.74 on Tuesday. The firm has a market capitalization of $435.84 million, a PE ratio of 574.57 and a beta of 1.88. ChromaDex has a 12 month low of $1.32 and a 12 month high of $6.18. The company’s 50 day simple moving average is $3.57 and its 200 day simple moving average is $3.24.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CDXC. SG Americas Securities LLC acquired a new stake in ChromaDex during the 1st quarter valued at $54,000. Acadian Asset Management LLC acquired a new stake in ChromaDex during the 1st quarter valued at $67,000. Lazard Asset Management LLC acquired a new stake in ChromaDex during the 1st quarter valued at $43,000. Perritt Capital Management Inc. acquired a new stake in ChromaDex during the 1st quarter valued at $139,000. Finally, Miracle Mile Advisors LLC acquired a new stake in ChromaDex during the 2nd quarter valued at $27,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Insiders Place Their Bets

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of ChromaDex stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 9.64% of the stock is currently owned by company insiders.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.